Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-19
    E.g., 2018-09-19

Archive Search

3 results
8:22 AM, May 04, 2018  |  BC Week In Review | Company News  |  Other News

Accelerator launches Proniras to develop anticonvulsant

conduct human clinical studies to determine safety and confirm dosing. Tezampanel is an inhibitor of glutamate ionotropic receptor kainate type subunit 1 (GluK1; GRIK1; GLUR5
12:57 PM, May 03, 2018  |  BC Innovations | Translation in Brief

New Therapeutic Targets and Biomarkers: April 2018

identified a phenylacetamide-based ULK1 activator that could help treat PD. Sichuan University Distillery Therapeutics Seizures Glutamate ionotropic receptor kainate type subunit 1 (GluK1; GRIK1; GLUR5
1:40 PM, Apr 27, 2018  |  BC Extra | Company News

Accelerator launches Proniras to develop anticonvulsant

conduct human clinical studies to determine safety and confirm dosing. Tezampanel is an inhibitor of glutamate ionotropic receptor kainate type subunit 1 (GluK1; GRIK1; GLUR5